The Institute for Clinical and Economic Review (ICER) frequently use RWE in their scoping process

  • All ICER reports of pharmaceuticals published between January 2014 and June 2019 were reviewed for the average number of instances and proportion of real-world evidence used in the scoping documents.
  • In the ICER scoping documents, the mean number of instances of real-world evidence use was 3.8 per document.


  • “There has been growing interest in using real-world evidence for health technology assessment (HTA) in the United States. [ICER] is an independent US-based HTA organization that focuses primarily on pharmaceuticals”
  • “[Real-world evidence] was frequently used in the ICER scoping process, particularly to inform selection of outcomes. [Real-world evidence] was used infrequently in ICER CCE assessments, while more often used to inform effectiveness, safety, and treatment patterns in relevant clinical guidelines”

Boshen Jiao, MPH, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute (December 2020)

Click here to read the source article and click here to read the original study abstract.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: JAN2021CW001